Introduction
The phosphatidyl inositol 3-kinase (PI3K)/AKT signaling pathway regulates a variety of basic cellular processes including, cell growth and survival, autophagy, metabolism and angiogenesis. This pathway is inappropriately activated, by multiple different mechanisms, in a broad spectrum of cancers [12] . Temsirolimus and everolimus (RAD001) are rapamcyin analogs that inhibit the mammalian target of rapamycin (mTOR), a major downstream effector of the PI3K/AKT network [25] . Treatment with rapamycin or its analogs results in cell cycle arrest and a host of indirect antitumor effects including a reduction of vascular endothelial growth factor (VEGF)-stimulated endothelial cell proliferation and migration [9, 30] .
Inhibition of VEGF and mTOR signaling has distinct effects on tumor vasculature and angiogenesis. In tumor models, inhibition of either VEGF or mTOR results in a potent decrease in blood vessel density. However there are differential effects on tissue permeability. While mTOR inhibition more strongly reduces the number of mature vessels, these agents do not decrease vascular tumor permeability, a classic marker of angiogenesis that is modulated by multiple agents that target VEGF. These important differences are likely accounted for by differential effects on tumor endothelial cells, smooth muscle cells and pericytes [23] . As such, in murine melanoma models, combination treatment with everolimus and the pan-VEGF receptor tyrosine kinase inhibitor, vatalanib, caused synergistic tumor growth inhibition in comparison to either monotherapy. These data suggest that everolimus may be a more effective therapy in combination with targeted inhibitors of VEGF signaling due to more complete inhibition of tumor vascularization [29] .
Bevacizumab is a humanized monoclonal antibody against VEGF and is approved by the Federal Drug Administration for the treatment of colorectal cancer [21] and non-squamous, non-small cell lung cancer in combination with chemotherapy [32] . It is also approved in combination with interferon α for the treatment of renal cell cancer [13] and as a single agent for progressive glioblastoma [39] . Multiple studies have reported that the combination of bevacizumab and everolimus is safe [1, 6, 17, 18, 35, 38] . Clinically significant toxicities include: fatigue, mucositis, hypertension, vomiting, diarrhea, proteinuria, fistula/abscess/perforation, and hemorrhage. These studies also demonstrated encouraging activity for the combination of bevacizumab with everolimus. In a population of patients with heavily pretreated solid tumors, the median progression free survival (PFS) was 6.0 months [6] . In a phase II trial of bevacizumab and everolimus in patients with refractory metastatic colorectal cancer (mCRC), median PFS interval was 2.3 months with 26 % of patients achieving prolonged stable disease for >6 months [1] . Eighty-four percent of these patients had documented progression on prior bevacizumab suggesting that this combination has modest activity in patients with refractory mCRC.
Capecitabine and oxaliplatin have activity in multiple gastrointestinal tumor types. The primary objective of this study was to define the maximal tolerated dose (MTD) and the recommended phase II dose (RPTD) for the combination of capecitabine, oxaliplatin, bevacizumab, and everolimus in subjects with advanced solid tumors. The secondary objectives were to investigate the pharmacodynamic characteristics of the combination and evaluate for signs of clinical activity. This study also provides additional information regarding the pharmacodynamic properties of bevacizumab and everolimus in patients with advanced solid tumors.
Patients and methods

Study design
This was a dose-escalation phase I study to assess the regimen of capecitabine (Genentech, South San Francisco, CA, USA), oxaliplatin, bevacizumab and everolimus (Novartis Pharmaceuticals, East Hanover, NJ, USA) in patients with advanced solid tumors. A standard phase I "3+3" design was used to establish the MTD/RPTD of the combination. The MTD was defined around toxicities in the first cycle; the RPTD was selected based upon toxicities occurring in all cycles. A cycle was defined as 21 days. The dose escalation schema is listed in Table 1 . Treatment was continued as long as patients were deemed to be clinically benefiting and until: disease progression, intercurrent illness that prevented further treatment, unacceptable toxicity, patient withdrawal from the study, or general or specific changes in the patient's condition that rendered further treatment inappropriate per judgment of the investigator or treating physician. Maximum time on treatment was capped at 2 years per protocol.
Patient selection
Eligible patients were required to have a histologically confirmed solid malignancy refractory to standard therapy or for which standard therapies did not exist or were no longer effective or for whom capecitabine, oxaliplatin, and/or bevacizumab would be considered a standard therapy or therapeutic option. Additional eligibility requirements included: age ≥18 years; Karnofsky performance status (KPS) ≥70 %; previous radiation therapy, hormonal therapy, biologic therapy or chemotherapy for cancer permitted ≥4 weeks prior to study drug; surgery permitted ≥4 weeks prior to study drug. Adequate organ and marrow function was defined as: absolute neutrophil count (ANC) ≥1,500/μl; platelets ≥100,000/μl; hemoglobin >9 g/dL; total bilirubin ≤1.5 times the upper limit of normal (ULN); aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤2.5 times ULN or ≤5 times ULN if known hepatic metastases; fasting serum cholesterol≤1.5 × ULN; fasting serum triglyceride≤2.5 × ULN; fasting blood sugar <160 mg/dL; creatinine clearance ≥50 mL/min/m 2 ; left ventricular ejection fraction ≥50 % and proteinuria ≤1 g/24 h. Additional exclusion criteria included: pregnancy, breastfeeding, central nervous system metastases, surgically resectable hepatic or pulmonary metastatic colorectal cancer, clinically significant cardiovascular disease with intervention within last 12 months, HIV or hepatitis B or C seropositivity, full dose anti-coagulation other than low molecular weight heparin, tumor invasion or encasement of a major artery, abdominal fistula or gastrointestinal perforation within 6 months of study drug, arterial thrombosis within past 12 months, bleeding diathesis or major bleed within 6 months of study drug, significant vascular or peripheral vascular disease, uncontrolled hypertension (blood pressure >140/ 90 mmHg) despite supportive care, history of hypertensive encephalopathy or crisis, chronic treatment with systemic steroids or another immunosuppressive agent, peripheral neuropathy of grade≥2, impairment of gastrointestinal function or gastrointestinal disease that may significantly alter drug absorption, evidence of interstitial lung disease, radiation to >25 % of bone marrow at any point. No history of hypersensitivity or intolerance with capecitabine, oxaliplatin, bevacizumab, or everolimus was permitted. Concurrent administration of medications with CYP3A4 or P-glycoprotein interactions (inhibitors, inducers or substrates) was not permitted. Serious medical conditions that might have significantly affected patient safety or toxicity assessment were prohibited.
This was a multi-center study (NCT00849550) approved by the institutional review boards of all participating sites and followed the guidelines of the Helsinki Declaration. All patients provided informed written consent prior to any studyrelated procedure and were treated at Duke University Medical Center ( 
Clinical and radiographic assessment
All patients completed an extensive medical history, baseline physical examination and clinical assessment prior to receiving study drug. Toxicity and safety assessments were performed weekly during cycle 1, then every 3 weeks prior to treatment and as clinically indicated. These assessments included vital signs, KPS, medical history, physical examination including complete blood count (CBC), chemistries including creatinine, alkaline phosphatase, AST, ALT, bilirubin, fasting lipid profile and urinalysis. Serum beta-human chorionic gonadotropin for women of child bearing potential, creatinine kinase (for patients on statin medications) thyroid stimulating hormone and electrocardiograms were assessed at baseline and every three cycles. Cardiac ejection fraction was assessed at baseline and as clinically indicated. General symptom management and supportive care such as antidiarrheal and anti-emetics agents were provided as clinically indicated to ensure optimal patient care. Computed tomography (CT) scan or magnetic resonance imaging (MRI) and blood tumor markers were completed within 4 weeks prior to the start of therapy and every three cycles (9 weeks) using RECIST criteria (version 1.0).
Safety
The National Cancer Institute Common Toxicity Criteria (NCI-CTC; version 3.0) was used to grade adverse events. The following adverse events were considered DLT in cycle 1: grade 4 neutropenia or thrombocytopenia lasting over 7 days; nausea/vomiting or diarrhea≥grade 3 and lasting≥4 days despite adequate supportive measures; febrile neutropenia where ANC <500/μl and temperature>101°F; hand foot syndrome grade≥3 lasting 7 or more days; grade≥3 neuropathy; grade≥ 3 hypophosphatemia lasting>24 h despite adequate supportive measures; grade ≥3 hyperglycemia lasting>7 days despite adequate supportive measures; grade ≥3 hypertriglyceridemia or hyperlipidemia lasting>28 days despite adequate supportive measures; other non-hematologic treatment related toxicity≥grade 3, excluding alopecia, anorexia, hypertension, isolated lab abnormalities (not clinically significant); rare, allergic and/or idiosyncratic reactions to any of the study agents of any severity; any treatment-related death or hospitalization; receiving less than 85 % of any of the planned study medication due to treatment-related toxicity. Subjects evaluable for DLT toxicity are defined as those subjects who give informed consent, meet inclusion/exclusion screening criteria and complete the full 21-day cycle of both study drug treatment and safety assessments. Subjects with informed consent who met the inclusion/exclusion criteria and received study drug treatment but did not complete the full 21-day cycle of study treatment and safety assessments for primary study end points 
, where C T is the threshold cycle.
Multiplex ELISA assays
EDTA plasma was obtained at baseline and after the third cycle of treatment. Samples were available from 22 evaluable patients. IL-6, HGF, VEGF, PDGF-β, VEGFR1, and TGFβ-2 were measured by ELISA methods SearchLight multiplex platform (Aushon Biosystems, Inc., Billerica, MA) according to the manufacturer's protocol. The TβRIII assay was performed as a stand-alone assay as previously described [24] . Briefly, samples for multiplex analysis were thawed on ice, centrifuged at 20,000×g for 5 min to remove any residual precipitate and appropriately diluted before placement onto SearchLight plates. Samples and standards were incubated at room temperature for 1 h while shaking. Plates were washed three times using an automated plate washer (Biotek Instruments, Inc., Model ELx405, Winooski, VT), biotinylated secondary antibody was added, and plates were then incubated for an additional 30 min. After three more washes, streptavidin-HRP was added to the plates, plates were incubated for 30 min, washed again, and SuperSignal substrate was added. Images of the plates were taken within 10 min, followed by image analysis using the SearchLight array analyst software (Version 2.1). Analyte concentrations were calculated based on a 6-point standard curve performed on each plate. Patient samples were tested in duplicate and the mean value was used for analysis.
Statistical analysis
The primary objective of this study is to determine the MTD. The DLTs of capecitabine, oxaliplatin, bevacizumab, and everolimus were tabulated by type and grade for all enrolled patients according to dose received. The number and percent of patients achieving complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) were summarized. PFS was defined as the time from randomization to progression of disease by RECIST or death, whichever comes first; patients who withdrew from the study for reasons other than progression or death were censored at the time of discontinuation from the study. Kaplan-Meier analyses and plots were used to estimate the PFS of treated patients. The response rate and PFS were to be summarized descriptively for all patients evaluable for efficacy. Biomarker analyses were considered exploratory. For the plasma data, Wilcoxon signed-rank tests were used to determine significant changes in biomarker on drug. For baseline plasma levels correlation with PFS, the data are limited to chemonaive patients with colorectal cancers. The log ratio (Lratio) defined as log 2 (on-treatment level/baseline level) were also investigated. Univariate biomarker correlations with PFS were evaluated using Cox proportional hazard regression analysis. Spearman's rank correlations were calculated for all pairs of RT-PCR biomarkers using both baseline and Lratio. Waterfall plots were produced using L-ratios to demonstrate how an analyte changes between the time points. Due the exploratory nature of all tests, p values were considered descriptive and were not corrected for multiple testing.
Results
Patient demographics
Patient demographics and tumor type are summarized in Table 2 . A total of 32 patients were enrolled and 31 patients were treated. One patient voluntarily withdrew consent prior to being treated due to development of an intercurrent illness. Twenty-nine patients were evaluable for toxicity; 30 were considered evaluable for radiographic tumor response. The median age was 58 years (range 25-74). Twenty-three of 31 (74 %) patients had metastatic colorectal cancer. Nine of 31 patients (29 %) had no prior chemotherapy treatment for metastatic disease.
Dose escalation and MTD determination
The dose escalation schema and corresponding DLTs are listed in Table 1 . Dose findings were based on overall safety and tolerability of the investigational drug combination. Two patients had treatment-related DLTs in cohort 1 (n=6). One patient experienced grade 2 intolerable fatigue, anorexia, nausea and vomiting and thus did not receive greater than 85 % of planned study medication despite maximal medical management. The second patient experienced transient grade 3 diarrhea and was also unable to receive 85 % of planned study medication. In cohort −1 (n=12), one DLT of grade 2 intolerable diarrhea was observed. In cohort −1b (n=13), everolimus was increased from 5 mg three times a week to 5 mg daily to maximize dose intensity. One subject in cohort −1b developed a treatment-related DLT, grade 3 rectovaginal fistula, which resulted in protocol discontinuation; this patient was not evaluable for efficacy. Two subjects, one in cohort 1 and one in cohort −1b, were not evaluable for toxicity due to intercurrent illness that was not study treatment related.
Safety
Most adverse events were mild to moderate and resolved with supportive clinical care and protocol-specified dose holdings and reductions. Grade ≥3 treatment-related toxicities across all cycles is summarized in Table 3 . Overall, the most common clinically significant grade ≥3 adverse events were hypertension (12.9 %), GI perforation/fistula (9.7 %) and diarrhea (6.5 %). There were two treatment related deaths: one due to rectal perforation and one due to GI hemorrhage. Both of these patients had metastatic cholangiocarcinoma and were in cohort −1b. The patient with the rectal perforation had no prior history of radiation and was concurrently noted to have disease progression. The patient with GI hemorrhage had evidence of a bleeding duodenal ulcer at the site of his prior surgical anastomosis. He had a remote history of adjuvant chemoradiation and his death was complicated by the fact that he declined blood product transfusion.
Efficacy
Patients were considered evaluable for efficacy if they underwent the first planned tumor assessment scan without clinical progression prior to the scan. For assessment of best response across all patients, 12 of 30 patients (40 %) had a PR and 12 of 30 patients (40 %) had SD (Fig. 1) . No CRs were noted. Six of 30 patients (20 %) had PD at the time of the first response assessment. Median PFS was 8.8 months (95 % CI 5.6-12.2 months). Four patients had not demonstrated radiologic or clinical progression at the time of study termination.
Twenty-two patients with colorectal tumors were evaluable for efficacy. Of the 15 patients that were chemonaive, 8 patients had a PR and 6 had SD (Fig. 1) . Of the 7 patients who had received prior chemotherapy for metastatic disease, three had a PR and 2 had SD All seven of these patients had been treated with prior 5-fluorouracil or capecitabine, five of seven had been treated with prior oxaliplatin and five of seven had been treated with prior bevacizumab. Three of 22 patients had disease progression at the time of first response assessment. Median PFS for all patients evaluable for efficacy with mCRC was 10.5 months (95 % CI 7.2-13.7 months). Median PFS for the chemonaive, mCRC patients was 12.9 months (95 % CI 7.2-20.9 months) and median PFS for the chemorefractory, mCRC patients was 6.8 months (95 % CI 1.8-10.5 months). Three patients with colorectal cancer had not demonstrated progression at the time of study termination. Two patients with colorectal cancer were on study therapy for 24 months without evidence of progression and thus were discontinued at that time per protocol.
Biomarker analysis
To evaluate biomarker responses to treatment, each subject's baseline biomarker profile was used as his or her reference control. Plasma samples collected at baseline and at the end of three cycles (first re-staging, on treatment) were available for biomarker analysis from 22 of the 31 treated patients. For each patient, seven biomarkers, IL-6, HGF, VEGF, PDGF-β, VEGFR1, TGFβ-2, and TβRIII were analyzed at baseline and on-treatment. Statistically significant changes were noted in TβRIII (p ≤ 0.00001) and IL-6 (p≤0.042) with both markers increasing on treatment ( Fig. 2a and b) . In the 11 patients who were evaluated on-treatment, it was noted that the change in PDGF-β levels was associated with PFS (p=0.035; data not shown).
We evaluated the mRNA levels of VEGF-A, VEGF-A isoforms, Neuropilin-1 (NRP1) and Neuropilin-2 (NRP2) by real-time quantitative RT-PCR in archived tissue from 22 patients. There was a correlation between higher levels of VEGF 165 and longer PFS (p=0.0076). Higher levels of total VEGF-A (p=0.094) and VEGF 121 (p=0.084) showed trends for a correlation with longer PFS (data not shown). There was no correlation between either NRP1 or NRP2 and outcome. To better understand the potential co-regulation of specific biomarkers, Spearman's rank correlation was used to test pairwise correlations. Pairs of baseline markers that reached statistical significance (correlation coefficients≥0.70, P≤0.005) included VEGF-A and NRP1, VEGF-A and VEGF 165 , VEGF-A and VEGF 189 , and VEGF 189 and VEGF 145 .
Discussion
The PI3K/Akt/mTOR signaling pathway is a key regulator of hypoxia and plays an important role in tumor angiogenesis [16] . VEGF-dependent and -independent mechanisms for the anti-angiogenic properties of mTOR inhibitors have been proposed. mTOR inhibition abrogates hypoxia-induced, transcription and accumulation of hypoxia-inducible factor alpha (HIF-1α), thus attenuating expression of the HIF-1α target gene, VEGF [5, 20] . Accumulation of HIF-1 has been postulated as a potential resistance mechanism to anti-angiogenic therapies such as bevacizumab [4, 11] . Furthermore, platelet derived growth factor (PDGF) signals to stem cell derived factor-1α(SDF-1α) via the PI3K/Akt/mTOR pathway to induce pericyte recruitment during angiogenesis [34] . This mechanism is also dependent on HIF-1α accumulation and activation. mTOR inhibition dissociates pericytes from the tumor vasculature, thus rendering the tumor more sensitive to anti-VEGF therapies [23] . Finally, the mTOR pathway is a critical for the differentiation of monocytes to proangiogenic, tumor associated macrophages (TAMs; M2 phenotype). Conversely, inhibition of mTOR modulates the polarity of macrophages to an antitumor M1 phenotype. These findings are independent of VEGF, reinforcing that mTOR inhibitors have effects on angiogenesis that are distinct and nonoverlapping with anti-VEGF therapies [7] . Based on this data we hypothesized that bevacizumab and everolimus in combination with chemotherapy would coordinately target parallel angiogenic signaling pathways and circumvent potential resistance mechanisms. In this phase I study, we demonstrated that everolimus could be safely combined with capecitabine, oxaliplatin and bevacizumab. However, the combination requires dose reductions in everolimus, capecitabine and oxaliplatin as full doses result in unacceptable, gastrointestinal toxicity. The MTD for everolimus in this combination was 5 mg daily, lower than the FDA approved monotherapy dose of 10 mg daily. It is also lower than other bevacizumab-everolimus combinations, suggesting that the addition of chemotherapy results in overlapping toxicity [1, 6, 17, 18] . Treatment-related toxicity was consistent with the known toxicity profiles of each of these agents when used separately. Four subjects experienced gastrointestinal fistula, perforation and/or hemorrhage, two of which were grade 5 (fatal) events. Perforation and related wound healing complications are well-described class effects of anti-VEGF therapies and anti-mTOR therapies [31, 33] . The frequency of this toxicity was potentially augmented by the combination of these agents, particularly in the setting of chemotherapy with gastrointestinal toxicities or where patients have had prior radiation therapy. The increased rate of fistula, perforation and hemorrhage has been noted in other studies investigating bevacizumab-everolimus combinations [1, 6] .
The combination of capecitabine, oxaliplatin, bevacizumab and everolimus demonstrated clinical activity. The partial response rate was 53 % in patients with chemonaive mCRC and several responses were seen in patients with refractory colorectal cancer and other tumor types. Of the 15 patients with mCRC that were chemonaive, two patients were on treatment for 2 years at which time study treatment was terminated per protocol. In addition, 2 of 11 chemorefractory patients, 1 with metastatic pancreatic cancer and the other with mCRC, were on treatment for 1 year (54.1 and 55.9 weeks respectively). Interestingly, the patient with mCRC had been treated with prior bevacizumab. These results suggest that this combination has sustained clinical activity in a subset of both chemonaive and chemorefractory patients with mCRC.
We measured the pharmacodynamic effects of capecitabine, oxaliplatin, bevacizumab and everolimus on several circulating biomarkers. Of the biomarkers analyzed, soluble TβRIII and IL-6 demonstrated statistically significant increases between baseline and the end of cycle 3. TβRIII (also known as betaglycan) is a TGF-β superfamily co-receptor that mediates ligand dependent and independent signaling (reviewed in [14] ). Regulation of TβRIII occurs at multiple levels with reductions in cell surface TβRIII being due to increased ectodomain shedding, thus producing a soluble TβRIII (sTβRIII). Soluble TβRIII functions either by sequestering TGF-β superfamily ligands and suppressing signaling or by binding to extracellular matrix proteins and thus blocking access to cell surface TβRIII. TβRIII expression may be prognostic, as loss of TβRIII expression increases with clinical stage in multiple tumor types, including ovarian, breast, prostate, and NSCLC [10, 14, 15] . More recent data has also demonstrated that in breast and melanoma tumor models, loss of TβRIII expression is associated with decreased tumor infiltrating CD8 + T cells and increased regulatory T cells within the tumor microenvironment, markers of more rapid disease progression [19] . Soluble TβRIII may also have therapeutic benefit as it has been shown to have tumor suppressive effects including inhibition of tumor growth, invasion and migration, angiogenesis and metastasis in multiple tumor types [2, 3, 10, 15] . Increases in soluble TβR3III have Fig. 2 Change from baseline to the end of cycle three for biomarkers with statistical significance (P value as indicated). Asterisk denotes patients who received prior systemic chemotherapy for metastatic disease not previously been described in response to bevacizumab or everolimus therapy but the lack of a randomized design, in the current study, prevents us from attributing the increase in soluble TβR3III to bevacizumab, everolimus, capecitabine, oxaliplatin or the combination. Further studies are warranted to explore this relationship.
In this study, plasma IL-6 levels were also noted to significantly increase on therapy but did not correlate with outcome. Elevated IL-6 levels are a well-documented adverse prognostic factor in multiple tumor types suggesting the importance of this pathway in driving tumor biology and clinical outcome [8, 22, 27, 36] . More recently, IL-6 has also been implicated as a predictive biomarker for both the oral multi-kinase inhibitor, pazopanib, and bevacizumab in patients with metastatic renal cell carcinoma. In the pivotal phase III study of pazopanib versus best supportive care, IL-6 had significant predictive value of PFS benefit. Patients with high IL-6 levels had a greater relative benefit from pazopanib compared with those who received placebo. However, a benefit from pazopanib therapy was also noted in the low IL-6 group [36] . Similarly, in CALGB 90206, a phase III trial of patients with advanced renal cell carcinoma randomized to bevacizumab + interferon versus interferon alone, IL-6 and hepatocyte growth factor (HGF) were predictive of overall survival in patients treated with bevacizumab + interferon [28] . While conclusions regarding the predictive ability of IL-6 must be viewed within the context of a given cancer type and therapeutic agent(s), these data certainly support ongoing study of the role of IL-6 in relation to other anti-angiogenic therapies.
Alternative splicing of the VEGF-A gene results in multiple VEGF-A isoforms that can diffuse over variable distances based on differential interactions with the extracellular matrix. In this study we investigated the role of tumor VEGF-A and VEGF-A isoforms in predicting benefit. We noted a statistically significant correlation between increased levels of tumor VEGF 165 mRNA and improved PFS. Furthermore, our data suggests coordinate regulation of VEGF-A and VEGF-A isoforms. The potential predictive role of plasma VEGF-A has now been supported by independent biomarker analyses in multiple tumor types. In the AVADO trial, a randomized phase III study of docetaxel +/− bevacizumab or placebo in patients with HER2-negative, metastatic breast cancer, predictive effect to bevacizumab was noted for high plasma VEGF-A and VEGFR-2 and blood mRNA for VEGF 121 but not VEGF 165. [26] . The AVAGAST study showed that the addition of bevacizumab to chemotherapy in patients with advanced gastric cancer improved response rate and PFS, but not OS. Baseline plasma VEGF-A levels and tumor neuropilin-1 expression were identified as potential predictors of bevacizumab efficacy [37] . The predictive value of VEGF-A to bevacizumab will be evaluated in ongoing, randomized studies. The phase III MERiDiAN trial (GO25632) began recruitment in 2012 and will prospectively evaluate the impact of bevacizumab in patients with metastatic breast cancer stratified by plasma VEGF-A levels.
In conclusion, we have demonstrated that the combination of everolimus at 5 mg daily, capecitabine at 680 mg/m 2 BID on days 1-14, oxaliplatin at 100 mg/m 2 and bevacizumab at 7.5 mg/kg given every 21 days appears safe and generally well tolerated. This regimen demonstrated activity and our data suggests that tumor levels of VEGF 165 may correlate with benefit. Furthermore, the combination modulated levels of sTβRIII and IL-6 suggesting a potential immunologic or anti-angiogenic mechanism of action.
